The American Journal of Managed Care | Special Issue: HCV

CLINICAL

In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.
Member cost negatively affects initial medication adherence and manufacturer coupons can decrease member share by up to 98%.
The authors examine real-world hepatitis C virus cure rates with direct-acting antivirals among patients coinfected with HIV.

COMMENTARY

As consensus on the shortsightedness of insurance restrictions on life-saving hepatitis C treatments continues to build, it’s time for private insurers and Medicaid programs to give all Americans suffering from this devastating disease a chance at a cure.
Despite the high cost of novel hepatitis C treatments and patients' apparent willingness to bear part of it, high patient cost sharing is both inefficient and inequitable.

FROM THE EDITORS

This special issue presents important new peer-reviewed research, covering issues ranging from access and the out-of-pocket costs of a treatment course, to the real-world consequences—both economic and clinical—of failing to treat.

POLICY

Expanding screening for hepatitis C virus infection may generate substantial benefits for patients and society, but only when paired with expanded treatment policies.
Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non–HCV-mediated liver failure.
Expanding private-payer coverage of hepatitis C treatment may yield significant long-term cost savings for private payers, reduced costs to Medicare, and increased social value.
This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.

More issues

$journals$
Compendia
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$vacMongoViewPlus$